Osmotica Pharmaceuticals plc (OSMT) Financials
$1.87
As on 22-Mar-2022 09:30EDT
Market cap
$92 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Cashflow ($ Mln) |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
17.59
|
33.57
|
37.56
|
57.84
|
-44.79
|
--
|
|||||
|
Cash Flow from Investing Activities
|
-3.08
|
-4.02
|
-4.13
|
-19.40
|
-453.46
|
--
|
|||||
|
Cash from Financing Activities
|
3.68
|
-4.69
|
3.60
|
-23.31
|
420.52
|
--
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Adjusted Book Value ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
Profitability Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
-22.69
|
-51.95
|
-15.68
|
-5.89
|
--
|
--
|
|||||
|
ROE (%)
|
-76.32
|
-108.15
|
-27.16
|
-10.21
|
--
|
--
|
|||||
|
ROA (%)
|
-19.08
|
-43.04
|
-13.01
|
-4.84
|
--
|
--
|
|||||
|
EBIT Margin (%)
|
-39.29
|
-116.57
|
-37.12
|
-23.03
|
-14.59
|
--
|
|||||
|
Net Margin (%)
|
-44.74
|
-112.86
|
-41.48
|
-18.37
|
-19.14
|
--
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.26
|
-0.09
|
0.07
|
0.12
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
75.02
|
-185.89
|
-72.95
|
-77.51
|
--
|
--
|
|||||
|
Net Profit Growth (%)
|
70.62
|
-147.63
|
-142.27
|
-7.97
|
--
|
--
|
|||||
|
EPS Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Price / Book Value
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-2.16
|
-0.80
|
-12.14
|
--
|
--
|
--
|
|||||
|
Close Price ($)
|
4.12
|
6.99
|
7.75
|
--
|
--
|
--
|
|||||
|
High Price ($)
|
9.67
|
9.35
|
9.90
|
--
|
--
|
--
|
|||||
|
Low Price ($)
|
2.81
|
2.20
|
6.21
|
--
|
--
|
--
|
|||||
|
Market Cap ($ Cr)
|
--
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
2.34
|
2.38
|
0.70
|
0.76
|
0.71
|
--
|
|||||
|
Short term debt to equity ratio
|
0.00
|
--
|
0.00
|
0.02
|
0.01
|
--
|
|||||
|
Current Ratio
|
3.10
|
2.27
|
1.51
|
0.92
|
0.80
|
--
|
|||||
|
Quick Ratio
|
2.78
|
1.99
|
1.29
|
0.79
|
0.63
|
--
|
|||||
|
Interest Coverage
|
--
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency Ratios |
Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 | Dec-12 | Dec-11 | Dec-10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.85
|
18.30
|
21.40
|
15.32
|
20.75
|
--
|
|||||
|
Asset Turnover
|
0.43
|
0.38
|
0.31
|
0.26
|
--
|
--
|
|||||
|
Receivable days
|
72.20
|
76.34
|
65.14
|
61.65
|
75.77
|
--
|
|||||
|
Inventory Days
|
96.21
|
74.74
|
55.90
|
53.66
|
57.69
|
--
|
|||||
|
Payable days
|
37.42
|
54.58
|
82.43
|
103.65
|
101.71
|
--
|
|||||
|
Cash Conversion Cycle
|
130.99
|
96.50
|
38.62
|
11.67
|
31.75
|
--
|